Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 77 Neoplasm Metastasis 8 Neoplasms 6 Prostatic Neoplasms, Castration-Resistant 5 Carcinoma, Non-Small-Cell Lung 4 Metastatic Castration-Resistant Prostate Cancer 3 Colorectal Neoplasms 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Castration-resistant Prostate Cancer 2 Carcinoma, Hepatocellular 2 Bulbo-Spinal Atrophy, X-Linked 2 Breast Neoplasms 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Solid Tumours 1 Salivary Gland Neoplasms 1 Prostatic Diseases 1

Interventions

Oxaliplatin 46 Gemcitabine 45 Fluorouracil 40 Capecitabine 31 pembrolizumab 29 Leucovorin 29 Docetaxel 27 Cisplatin 25 Paclitaxel 23 Irinotecan 18 Carboplatin 18 Bevacizumab 18 130-nm albumin-bound paclitaxel 17 Pemetrexed 15 Albumin-Bound Paclitaxel 15 Radiotherapy 14 Nivolumab 12 Ramucirumab 11 Cyclophosphamide 11 Trastuzumab 8 Erlotinib Hydrochloride 8 Taxes 7 Radiosurgery 7 Drug Therapy 7 cemiplimab 6 zolbetuximab 5 trastuzumab deruxtecan 5 regorafenib 5 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × abiraterone × Clear all

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡